Chong Kun Dang Pharmaceutical Corporation

Samsung Electronics Co., Ltd.

Hyundai Motor Company

Kia Motors Corporation

So Hyun Park

Min Hyo Ki

Jin Young Ko

Tae Jin Park

Ji Yeon Kim

Yoo Sang Hwang

Jong Lae Lim

Hyo-Sub Kim

Keun Nam Kim

Sang Myoung Noh

Sung Won An

Seung Yeub Lee

Ha Na Yu

Jin Ha Jeong

Hee Jin Jung

Byoung Ki Ahn

Won Kyu Yang

Won Seok Yoo

Se Jin Han

Sang Phil Yoon

Jeong Woo Kang

Sung Bum Jung

In Kyoung Heo

Hye Jung Baik

Ki Seong Ko

Ji Youn Han

Young Gun Cho

Tae Hyun Park

The present invention relates to an injectable composition of testosterone ester for the treatment of testosterone deficiency. Particularly, the present invention relates to a pharmaceutical composition comprising testosterone undecanoate, which is capable of increasing the convenience for use in injection with the low viscosity and injection force, and has improved stability.

Stable pharmaceutical composition comprising testosterone undecanoate

A semiconductor device is provided. The semiconductor device includes a substrate a bit line structure disposed on the substrate, a trench adjacent to at least one side of the bit line structure, a storage contact structure disposed within the trench, and comprising a storage contact, a silicide layer, and a storage pad which are stacked sequentially. A spacer structure is disposed between the bit line structure and the storage contact structure.

Semiconductor device including a spacer in contact with an upper surface of a silicide layer

A quick connector is provided. The quick connector is configured to be coupled to a locking ring provided around an outer peripheral surface of a tube, through which fluid flows in or out. The quick connector includes a main body, which accommodates the tube therein and includes locking members, formed to be locked by the locking ring and being bent toward the locking ring, and a mounting guide coupled to the outer peripheral surface of the main body and accommodating the locking members therein. The mounting guide is configured to slide along the longitudinal axis of the main body so as to enable the locking members to be locked around the locking ring or to be released from the locked state.

Quick connector

Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more &#x2014;OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.

Sustained-release lipid pre-concentrate of GNRH analogues and pharmaceutical composition comprising the same

Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more &#x2014;OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided.

Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same

Growing community of inventors

Yongin-si, South Korea

So Hyun Park